Clinical profiling, antifungal drug susceptibility, and biofilm formation ability in pulmonary mucormycosis
BMC Microbiology · 04.11.2025 · 25 (1)
DOI: 10.1186/s12866-025-04472-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift BMC Microbiology, online erschienen am 04.11.2025. Verfasst von Peng Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Clinical Microbiology, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medica…. Hauptthemen laut MEDLINE: Biofilms, Antifungal Agents, Mucormycosis, Mucorales. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Beijing Municipality, National Natural Science Foundation of China, Reform and Development Program of Beijing Institute of Respiratory Medicine.
Abstract (Originalsprache)
Pulmonary mucormycosis (PM), a life-threatening infection caused by Mucorales, exhibits high mortality. Comprehensive data integrating clinical profiling, antifungal susceptibility, and biofilm formation ability are limited. This retrospective study characterized 26 adult PM patients at a Beijing tertiary-care hospital. Data on demographics, underlying diseases, co-infections, and outcomes were collected. Clinical Mucorales isolates underwent molecular identification via 18 S rRNA gene sequencing and phylogenetic analysis. In vitro susceptibility against nine antifungals (amphotericin B, fluconazole, voriconazole, itraconazole, posaconazole, caspofungin, micafungin, anidulafungin, 5-flucytosine) was determined using Sensititre YeastOne YO10 panels. Biofilm biomass was assessed (24 h, 48 h, 72 h) via the crystal violet staining assay. Patients were predominantly older males (median age 66 years, 65.4% male) with high comorbidity burden (92.3%). All-cause in-hospital mortality was 38.5%. Strikingly, 80.8% had co-infections. Temporal analysis revealed that viral (77.8%) and fungal (62.5%) co-infections often preceded the detection of Mucorales. Molecular identification confirmed Rhizopus spp. (54%) predominated, followed by Rhizomucor spp. (19%), Mucor spp. (19%), and Lichtheimia spp. (8%). Antifungal testing showed amphotericin B possessed the most consistent activity (MIC50/MIC90: 1/2 µg/mL). Posaconazole was the most potent azole (MIC50/MIC90: 0.25/1 µg/mL), but profound genus-level heterogeneity was observed. Biofilm assessment at the 48-h peak revealed biofilm formation in 84.6% (22/26) of isolates. This study highlights the high prevalence of antecedent viral/fungal co-infections preceding Mucorales detection and significant mortality, despite in vitro susceptibility to amphotericin B/posaconazol. In addition, most of the strains demonstrated biofilm formation ability, with evident genus-level heterogeneity. These findings emphasize the imperative of species-level identification and consideration of genus-specific traits to guide effective management of this life-threatening infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases and Clinical Microbiology, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
- Department of Clinical Laboratory, The First Affiliated Hospital, Sun Yat- sen University, Guangzhou, China.
- Department of Clinical Laboratory, Beijing Hospital, Chinese Academy of Medical Sciences, Beijing, China.
- Department of Clinical Laboratory, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
- Department of Infectious Diseases and Clinical Microbiology, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. weiming@bjmu.edu.cn.
- Department of Infectious Diseases and Clinical Microbiology, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. wangpkq@163.com.
Förderung
- Natural Science Foundation of Beijing Municipality
- National Natural Science Foundation of China
- Reform and Development Program of Beijing Institute of Respiratory Medicine
Zitieren
APA
Wang, P., Peng, Y., Liu, J., Li, T., Zhang, D., Gu, L., Wang, Q., Su, M., Wei, M., & Wang, S. (2025). Clinical profiling, antifungal drug susceptibility, and biofilm formation ability in pulmonary mucormycosis. BMC Microbiology, 25(1). https://doi.org/10.1186/s12866-025-04472-9
Vancouver
Wang P, Peng Y, Liu J, Li T, Zhang D, Gu L, et al. Clinical profiling, antifungal drug susceptibility, and biofilm formation ability in pulmonary mucormycosis. BMC Microbiology. 2025;25(1). doi:10.1186/s12866-025-04472-9
BibTeX
@article{Wang2025,
author = {Wang, Peng and Peng, Yaqin and Liu, Jun and Li, Tianmeng and Zhang, Dan and Gu, Li and Wang, Qiangyi and Su, Mingze and Wei, Ming and Wang, Shuai},
title = {Clinical profiling, antifungal drug susceptibility, and biofilm formation ability in pulmonary mucormycosis},
journal = {BMC Microbiology},
year = {2025},
volume = {25},
number = {1},
doi = {10.1186/s12866-025-04472-9}
}
EUVIMED